Amneal Pharmaceuticals, Inc. AMRX AvKARE — Net revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s avkare — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — net revenue of $166.02M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s avkare — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s avkare — net revenue decreased by 3.7% year-over-year, from $172.42M to $166.02M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — net revenue?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — net revenue has grown at a 20.9% compound annual growth rate (CAGR), from $349.01M to $744.73M.
- What does avkare — net revenue mean?
- Represents the total gross sales generated by the AvKARE business segment after accounting for returns, allowances, and discounts. This metric serves as a primary indicator of the segment's market demand and top-line growth trajectory within the pharmaceutical distribution and government contracting space.